workshop program

This course is designed for individuals who want to understand the rationale, methodology and importance of in vitro ADMET studies during the drug discovery and development processes. Example attendees include, medicinal chemists wishing to understand the importance of early ADMET testing, and project managers wanting to understand the DMPK and safety profiles of lead compounds.

The various types of in vitro ADMET studies will be discussed, detailing the benefits of performing these assays early in drug discovery, an overview of the methodologies currently available, and how these data can be used to make informed decisions based upon a compound's overall ADMET profile.

1:00 – 1:10	Clive Dilworth, Director of Scientific Operations (UK), Cyprotex Introduction and Overview
1:10 – 1:50	Clive Dilworth, Director of Scientific Operations (UK), Cyprotex Membrane Permeability and Drug Transporters
1:50 – 2:50	Michael Griffin, Senior Principal Scientist, Cyprotex In Vitro Drug Metabolism
2:50 - 3:05	Break
3:05 - 4:00	Clive Dilworth, Director of Scientific Operations (UK), Cyprotex CYP450 Mediated Drug-Drug Interactions
4:00 - 5:00	Chris Strock, Senior Scientist, Cyprotex Early In Vitro Toxicity Assays in Drug Development

7:30 - 8:30	Registration & Breakfast
“De-Risking Drug Discovery Programs Early. From Early ADME to Early Safety – Which Assays Give the Most Value.”
8:30 - 8:50	Katya Tsaioun, Ph.D., Chief Scientific Officer, Cyprotex Introduction and Welcome
Part I. Bringing Toxicity Screening to the Front: Reducing Late Compound Attrition Risks Via New Approaches
8:50 - 9:30	Arthur M. “Buzz” Brown, M.D., Chairman, ChanTest Perfecting Risk Assessment of Cardiotoxicity
9:30 - 10:10	Vincent Murphy, Ph.D., Principal Research Investigator, Array BioPharma The Value of the SC-hCM APD Assay in Conjunction with other In Vitro Assays and In Vivo Telemetry to Assess Cardiac Risk
10:10 - 10:40	Networking Coffee Break
10:40 - 11:20	Grace Furman, Ph.D., CEO and President, Paracelsus Building Confidence in Cardiac Safety During Lead Optimization
11:20 - 12:00	Katya Tsaioun, Ph.D., Chief Scientific Officer, Cyprotex New Technologies for Mechanistic Toxicology in Lead De-Risking: from CellCiphr™ 1.0 to CellCiphr™ 2.0.
12:00 - 1:00	Networking Lunch
Part II: Optimizing DMPK: Approaches Used by Pharmaceutical Companies and their Expectations from Academic Partners
1:00 - 1:40	Bernard Murray, Ph.D., Senior Research Scientist I, Drug Metabolism, Gilead Targeted Solutions to DMPK Problems: Avoiding Unnecessary Screening
1:40 - 2:20	James M. Schmidt, Sr. Research Scientist, Drug Metabolism, Lexicon Pharmaceuticals The Importance of Stereo-Selective Drug Metabolism in Drug Discovery
2:20 - 2:50	Networking Coffee Break
2:50 - 3:30	Hakim Djaballah, Ph.D., Director, HTS Core Facility, Memorial Sloan-Kettering Cancer Center Drug Discovery and Development in Academia: The Sloan Kettering Experience
3:30 - 4:10	Berend Oosterhuis, Director of Business Development and Contract Research Services, Solvo Biotechnology Transporter Assays: When and How to Utilize Them
4:10 - 5:00	Panel Discussion: All Speakers Ask the experts your questions about how to address DMPK and safety issues in your programs.
5:00 - 7:00	Closing Reception